Alyeska Investment Group
PNT

Alyeska Investment Group’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Alyeska Investment Group’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-346,171
Closed -$2.68M – 534
2022
Q3 		$2.68M Sell
346,171
-465,207
-57% -$3.95M 0.03% 304
2022
Q2 		$5.53M Sell
811,378
-36,539
-4% -$280K 0.06% 280
2022
Q1 		$6.76M Hold
847,917
– – 0.07% 258
2021
Q4 		$4.75M Buy
847,917
+26,895
+3% +$202K 0.05% 296
2021
Q3 		$6.31M Buy
821,022
+76,822
+10% +$701K 0.08% 279
2021
Q2 		$7.54M Buy
+744,200
New +$7.57M 0.09% 262

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Alyeska Investment Group's PNT Position: Q4 2022 in Review

Alyeska Investment Group sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2022, closing a stake of 346,171 shares — an estimated $2.68M sold.

Alyeska Investment Group first reported a position in PNT in Q2 2021 and held it in 6 quarters. The position peaked at $7.54M in Q2 2021. 109 funds tracked by Wall St. Rank hold PNT as of Q4 2022.

  • Alyeska Investment Group reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 346,171 POINT Biopharma Global Inc. Common Stock shares in Q4 2022, an estimated $2.68M.
  • Alyeska Investment Group first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2021 and held it in 6 quarters.
  • Alyeska Investment Group's POINT Biopharma Global Inc. Common Stock position peaked at $7.54M in Q2 2021.
  • 109 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2022.

Based on Alyeska Investment Group's 13F filing for Q4 2022, filed 14 Feb 2023.